# ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

> **NCT04387539** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 94 (actual)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/SMV/DCV/RBV

## Key facts

- **NCT ID:** NCT04387539
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2017-10-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387539, "ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT04387539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*